CA
NZ
UK
AU
IND
US
…
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Income before tax | -160.48M | -125.61M | 71.92M | -111.43M | -77.30M |
| Net income | -147.03M | -116.95M | 66.97M | -111.14M | -77.68M |
| Selling general administrative | 61.84M | 49.90M | 46.32M | 38.70M | 35.74M |
| Gross profit | 82.96M | 53.91M | 200.58M | 0.85M | -50.02M |
| Reconciled depreciation | 0.93M | 0.74M | 6.80M | 6.98M | 6.82M |
| Ebit | -191.04M | -131.56M | 71.97M | -112.73M | -85.70M |
| Ebitda | -190.11M | -130.81M | 78.78M | -105.76M | -85.82M |
| Depreciation and amortization | 0.93M | 0.74M | 6.80M | 6.98M | -0.12M |
| Non operating income net other | - | - | -0.10M | -0.06M | 0.20M |
| Operating income | -191.04M | -131.56M | 71.97M | -112.73M | -85.70M |
| Other operating expenses | 282.41M | 185.46M | 128.60M | 113.59M | 86.57M |
| Interest expense | - | 6.70M | 6.75M | 8.28M | 8.20M |
| Tax provision | -13.45M | -8.66M | 4.95M | -0.28M | 0.38M |
| Interest income | 31.01M | 6.35M | 0.04M | 1.37M | 8.20M |
| Net interest income | 31.01M | 6.35M | 0.04M | 1.37M | 8.20M |
| Non recurring | - | - | - | - | -0.06M |
| Income tax expense | -13.45M | -8.66M | 4.95M | -0.28M | 0.38M |
| Total revenue | 91.37M | 53.91M | 200.58M | 0.85M | 0.81M |
| Total operating expenses | 282.41M | 185.46M | 128.60M | 113.59M | 86.57M |
| Cost of revenue | 8.41M | 6.74M | 82.28M | 74.88M | 50.84M |
| Total other income expense net | 30.56M | 5.95M | -0.05M | 1.31M | 8.40M |
| Net income from continuing ops | -147.03M | -116.95M | 66.97M | -111.14M | -77.68M |
| Net income applicable to common shares | - | -116.95M | 66.97M | -111.14M | -77.68M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 696.38M | 758.03M | 609.37M | 332.98M | 419.27M |
| Other current assets | 19.10M | 8.69M | 5.71M | 2.54M | 2.65M |
| Total liab | 135.02M | 135.99M | 143.32M | 148.97M | 146.35M |
| Total stockholder equity | 561.37M | 622.04M | 466.04M | 184.01M | 272.92M |
| Deferred long term liab | - | - | 102.93M | 110.24M | 110.24M |
| Other current liab | -37.02M | 22.96M | 16.16M | 11.29M | 6.79M |
| Common stock | 0.54M | 0.52M | 0.47M | 0.40M | 0.40M |
| Capital stock | 0.54M | 0.52M | 0.47M | 0.40M | 0.40M |
| Retained earnings | -980.03M | -833.00M | -716.05M | -783.03M | -671.88M |
| Other liab | - | 85.85M | 103.49M | 110.80M | 110.80M |
| Other assets | - | 30.93M | 10.42M | 31.14M | 13.74M |
| Cash | 620.18M | 710.41M | 579.09M | 295.38M | 375.72M |
| Total current liabilities | 56.89M | 50.15M | 33.45M | 25.85M | 17.71M |
| Current deferred revenue | 67.41M | 11.44M | 7.66M | 4.93M | 4.58M |
| Net debt | -608.35M | -703.93M | -566.77M | -277.54M | -352.78M |
| Short term debt | 1.11M | 6.47M | 5.94M | 5.51M | 5.10M |
| Short long term debt total | 11.84M | 6.47M | 12.33M | 17.84M | 22.94M |
| Other stockholder equity | 1540.86M | 1454.52M | 1181.63M | 966.64M | 944.41M |
| Property plant equipment | - | 8.01M | 2.01M | 2.55M | 3.87M |
| Total current assets | 639.28M | 719.10M | 584.81M | 299.28M | 378.38M |
| Net tangible assets | - | 622.04M | 466.04M | 184.01M | 272.92M |
| Net receivables | 5.16M | 0.06M | 0.01M | 0.01M | 0.07M |
| Inventory | -5.16M | -0.06M | - | 1.35M | -0.07M |
| Accounts payable | 25.39M | 9.27M | 3.69M | 4.12M | 1.24M |
| Accumulated other comprehensive income | - | - | - | - | -8.01M |
| Common stock total equity | - | - | 0.47M | 0.40M | 0.40M |
| Retained earnings total equity | - | - | -716.05M | -783.03M | -671.88M |
| Non currrent assets other | 40.24M | 12.72M | 3.35M | 1.69M | 3.79M |
| Deferred long term asset charges | - | - | - | - | 9.96M |
| Non current assets total | 57.10M | 38.94M | 24.56M | 33.69M | 40.89M |
| Capital lease obligations | 11.84M | 6.47M | 12.33M | 17.84M | 22.94M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Investments | -1.41M | -0.46M | -0.57M | -0.20M | -0.55M |
| Change to liabilities | - | -1.99M | -0.14M | 7.73M | -0.54M |
| Total cashflows from investing activities | - | -0.46M | -0.57M | -0.20M | -0.55M |
| Total cash from financing activities | 45.10M | 241.46M | 190.33M | 0.21M | 0.23M |
| Change to operating activities | - | -16.81M | -10.28M | -4.30M | -4.37M |
| Net income | -147.03M | -116.95M | 66.97M | -111.14M | -77.68M |
| Change in cash | -90.22M | 132.17M | 282.36M | -80.34M | -53.29M |
| Begin period cash flow | 710.41M | 580.45M | 298.08M | 378.43M | 431.71M |
| End period cash flow | 620.18M | 712.62M | 580.45M | 298.08M | 378.43M |
| Total cash from operating activities | -133.91M | -108.82M | 92.61M | -80.36M | -52.97M |
| Issuance of capital stock | 232.78M | 223.62M | 174.79M | 78.37M | - |
| Depreciation | 0.93M | 0.74M | 6.80M | 6.98M | 6.82M |
| Other cashflows from investing activities | - | - | - | - | 0.01M |
| Change to inventory | -8.90M | - | -10.28M | - | - |
| Change to account receivables | -5.16M | 0.08M | 0.01M | 0.05M | 0.05M |
| Sale purchase of stock | - | - | 93.59M | 0.21M | 0.23M |
| Other cashflows from financing activities | 45.10M | 17.84M | 190.33M | 0.21M | 0.23M |
| Change to netincome | - | 20.19M | 4.57M | -1.69M | -1.25M |
| Capital expenditures | 2.81M | 0.46M | 0.57M | 0.20M | 0.56M |
| Change receivables | - | - | 0.01M | 0.05M | - |
| Cash flows other operating | - | - | 20.07M | 23.18M | 24.93M |
| Cash and cash equivalents changes | - | - | 282.36M | -80.34M | -53.29M |
| Change in working capital | -20.53M | -18.80M | -10.40M | 3.48M | -4.45M |
| Stock based compensation | 40.91M | 31.32M | 24.66M | 22.01M | 23.59M |
| Other non cash items | 7.50M | 6.00M | 38.74M | 28.19M | 51.35M |
| Free cash flow | -136.72M | -109.28M | 92.03M | -80.56M | -53.52M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| PRTA Prothena Corporation plc |
-0.41 4.62% |
8.47 | - | 64.10 | 13.08 | 2.13 | 6.43 | -3.09 |
| NVO Novo Nordisk A/S |
0.86 2.20% |
40.00 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
18.88 3.50% |
558.88 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
109.12 13.33% |
927.89 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.
| Name | Title | Year Born |
|---|---|---|
| Dr. Gene G. Kinney Ph.D. | Pres, CEO & Director | 1969 |
| Mr. Tran B. Nguyen M.B.A. | CFO & Chief Strategy Officer | 1974 |
| Mr. Brandon S. Smith | Chief Operating Officer | 1975 |
| Ms. Carol D. Karp | Chief Regulatory Officer | 1953 |
| Dr. Hideki Garren M.D., Ph.D. | Chief Medical Officer | 1965 |
| Ms. Karin L. Walker CPA, CPA | Chief Accounting Officer & Controller | 1963 |
| Dr. Wagner M. Zago | Chief Scientific Officer | 1973 |
| Ms. Jennifer Zibuda | Director of Investor Relations & Communication | NA |
| Mr. Michael J. Malecek | Chief Legal Officer | 1966 |
| Ms. Yvonne M. Tchrakian | Company Sec. | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.82%
Communication Services
-0.22%
Consumer Cyclical
-0.13%
Consumer Defensive
+0.32%
Energy
+0.15%
Financial Services
-0.85%
Financials
+2.34%
Healthcare
-1.28%
Industrials
-0.96%
Real Estate
-0.38%
Technology
-2.73%
Utilities
-0.31%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...